Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial

IMPORTANCE: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). OBJECTI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Neurol
Hauptverfasser: Healey, Jeff S., Gladstone, David J., Swaminathan, Balakumar, Eckstein, Jens, Mundl, Hardi, Epstein, Andrew E., Haeusler, Karl Georg, Mikulik, Robert, Kasner, Scott E., Toni, Danilo, Arauz, Antonio, Ntaios, George, Hankey, Graeme J., Perera, Kanjana, Pagola, Jorge, Shuaib, Ashfaq, Lutsep, Helmi, Yang, Xiaomeng, Uchiyama, Shinichiro, Endres, Matthias, Coutts, Shelagh B., Karliński, Michal, Czlonkowska, Anna, Molina, Carlos A., Santo, Gustavo, Berkowitz, Scott D., Hart, Robert G., Connolly, Stuart J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2019
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583060/
https://ncbi.nlm.nih.gov/pubmed/30958508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.0617
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge